Recoflavone

Drug Profile

Recoflavone

Alternative Names: DA-6034

Latest Information Update: 03 Sep 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dong-A Pharmaceutical
  • Developer Dong-A Pharmaceutical; Dong-A ST
  • Class Anti-inflammatories; Antiallergics; Benzopyrans; Eye disorder therapies; Flavonoids; Small molecules
  • Mechanism of Action Antioxidants; Calcium channel agonists; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Dry eyes; Gastritis

Highest Development Phases

  • Phase III Gastritis
  • Phase II Dry eyes
  • Discontinued Crohn's disease; Ulcerative colitis

Most Recent Events

  • 03 Sep 2015 Phase-II development is ongoing for Dry eyes
  • 03 Sep 2015 Phase-III development is ongoing for Gastritis
  • 31 Aug 2013 Dong-A ST completes a phase III trial in Gastritis in South Korea (NCT01813812)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top